CIK 0001785530
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Werewolf Therapeutics, Inc.
Sign in to watch- Ticker
- HOWL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 823523180
- Phone
- +1 617-952-0555
- Business address
- 303 WYMAN STREET, SUITE 300, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-01-06 | Leonard Reid Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +70,967 | 70,967 | ||
| 2022-01-06 | Trost Timothy W. Chief Financial Officer | Grant or award · Stock Option (right to buy) | +65,960 | 65,960 | ||
| 2022-01-06 | HICKLIN DANIEL J | Grant or award · Stock Option (right to buy) | +215,888 | 215,888 | ||
| 2022-01-06 | Lubman Ellen Chief Business Officer | Grant or award · Stock Option (right to buy) | +51,088 | 51,088 | ||
| 2022-01-06 | Karunatilake Chulani Chief Technology Officer | Grant or award · Stock Option (right to buy) | +34,258 | 34,258 | ||
| 2022-01-06 | Seidel-Dugan Cynthia Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +79,516 | 79,516 | ||
| 2021-12-30 | Leonard Reid Chief Operating Officer | Exercise or conversion | +14,102 | $1.56 | $22K | 14,102 |
| 2021-12-30 | Leonard Reid Chief Operating Officer | Exercise or conversion · Stock Option (Right to Buy) | −14,102 | 47,034 | ||
| 2021-12-15 | Leonard Reid Chief Operating Officer | Sale | −2,865 | $13.39 | $38K | 122,292 |
| 2021-12-15 | Leonard Reid Chief Operating Officer | Sale | −135 | $13.97 | $2K | 122,157 |
| 2021-10-28 | Chatterjee Meeta Director | Grant or award · Stock Option (right to buy) | +23,200 | 23,200 | ||
| 2021-07-01 | Karunatilake Chulani Chief Technology Officer | Grant or award · Stock Option (right to buy) | +272,000 | 272,000 | ||
| 2021-06-16 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +9,285 | $13.37 | $124K | 4,291,881 |
| 2021-06-15 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +7,958 | $12.95 | $103K | 4,282,596 |
| 2021-06-14 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | +306,055 | $12.75 | $3.9M | 4,274,638 |
| 2021-05-27 | Sherman Michael A. Director | Grant or award · Stock Option (right to buy) | +23,200 | 23,200 | ||
| 2021-05-04 | MPM BioVentures 2014, L.P. 10% owner | Conversion | +2,298,430 | 2,298,430 | ||
| 2021-05-04 | MPM BioVentures 2014, L.P. 10% owner | Conversion | +763,809 | 3,062,239 | ||
| 2021-05-04 | MPM BioVentures 2014, L.P. 10% owner | Purchase | +125,759 | $16.00 | $2.0M | 3,187,998 |
| 2021-05-04 | MPM BioVentures 2014, L.P. 10% owner | Conversion · Series A Preferred Stock | −19,925,321 | 0 |
Page 13 of 17 · 335 trades